Longpre Lara
SEC CIK 1780347 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | Chief Development Off | 104.4K | $10.3K | $115.7K | 14 | 2019-09-10 | 2024-02-02 |
Most active insiders at MIRM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Peetz Christopher | CEO, Dir | — | $16.29M |
| 2 | GREY MICHAEL G | Dir | — | $11.10M |
| 3 | Heron Patrick J | Dir | $9.00M | — |
| 4 | Howe Jolanda | SVP, Gbl Ctrl | — | $5.55M |
| 5 | BJERKHOLT ERIC | CFO | — | $3.56M |
| 6 | Radovich Peter | Pres AND COO | — | $2.32M |
| 7 | Ramasastry Saira | Dir | — | $1.92M |
| 8 | Quan Joanne | Chief MEDICAL Off | — | $1.46M |
| 9 | Cardon Lon | Dir | — | — |
| 10 | Fischer Laurent | Dir | — | — |
Longpre Lara made no open-market trades at MIRM in the last 12 months.
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-18 | 2023-01-09 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief DEVELOPMENT Off | S - Sale | $20.62 | -1,003 | 104.4K | -1.0% | -$20.7K | |
| 2024-03-18 | 2019-09-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief DEVELOPMENT Off | P - Purchase | $10.64 | +965 | 105.4K | +0.9% | +$10.3K | |
| 2024-02-05 | 2024-02-02 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief DEVELOPMENT Off | S - Sale | $26.19 | -847 | 104.4K | -0.8% | -$22.2K | |
| 2024-01-09 | 2024-01-08 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief DEVELOPMENT Off | S - Sale | $28.04 | -1,019 | 105.3K | -1.0% | -$28.6K | |
| 2023-11-15 | 2023-11-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $22.29 | +434 | 106.3K | +0.4% | +$9,674 | |
| 2023-07-05 | 2023-07-03 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | S - Sale | $25.65 | -1,004 | 105.8K | -0.9% | -$25.8K | |
| 2023-05-19 | 2023-05-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $16.92 | +684 | 106.8K | +0.6% | +$11.6K | |
| D | 2023-02-02 | 2023-01-31 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $0.00 | +9,625 | 106.2K | +10% | $0 |
| 2022-11-14 | 2022-11-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $17.05 | +82 | 96.5K | +0.1% | +$1,398 | |
| 2022-05-12 | 2022-05-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $13.57 | +1,454 | 96.5K | +2% | +$19.7K | |
| D | 2022-01-07 | 2022-01-06 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $0.00 | +10.0K | 95.0K | +12% | $0 |
| 2021-11-15 | 2021-11-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $13.52 | +753 | 85.0K | +0.9% | +$10.2K | |
| 2021-10-01 | 2021-10-01 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | S - Sale | $19.26 | -961 | 84.2K | -1% | -$18.5K | |
| 2021-10-01 | 2021-09-29 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Off | A - Grant | $0.00 | +8,125 | 85.2K | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations